ANIX insider trading
NasdaqCM HealthcareAnixa Biosciences Inc: insider trade history from SEC Form 4 filings.
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Company website: www.anixa.com
ANIX insider activity at a glance
FilingIQ tracks 129 insider transactions for ANIX in filings since Oct 25, 2018. The most recent transaction is dated Oct 22, 2026.
Across the full history, 99 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest ANIX Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at ANIX
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for ANIX?
- FilingIQ tracks 129 Form 4 insider transactions for ANIX (Anixa Biosciences Inc), covering filings from Oct 25, 2018 onwards. 13 of those are dated within the last 90 days.
- Are ANIX insiders net buyers or net sellers?
- Across the full Form 4 history for ANIX, 99 transactions (77%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ANIX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is ANIX in?
- Anixa Biosciences Inc (ANIX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $88.18M.
Methodology & sources
Every ANIX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.